🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Epinephrine Inhalation Aerosol, HFA

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  2. Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

    phase 2 small molecule terminated

    1 trial

  3. Estradiol , estriol , progesterone

    CNS Pharmaceuticals

    Menopause

    phase 2 small molecule terminated

    1 trial

  4. EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  5. Etrasimod

    Arena Pharmaceutical Enterprises Limited

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  6. Etripamil

    Milestone Pharmaceuticals

    Atrial Fibrillation

    phase 2 small molecule completed

    1 trial

  7. Etripamil

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia (PSVT)

    phase 2 small molecule completed

    1 trial

  8. Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 other active

    1 trial

  9. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial

  11. Exaluren

    Eloxx Pharmaceuticals

    Alport Syndrome, X-Linked

    phase 2 small molecule active

    1 trial

  12. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  13. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  14. Experimental: CHF6001 3200 μg

    Chiesi Farmaceutici S.p.A.

    Uncontrolled Asthma

    phase 2 small molecule terminated

    1 trial

  15. FGF401

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule completed

    1 trial

  16. FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  17. FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, YTB323

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 small molecule active

    1 trial

  18. FLUDARABINE PHOSPHATE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, BENDAMUSTINE, PHE885

    Novartis Pharmaceuticals

    Adult patients with relapsed and refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  19. FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  20. FLUOROURACIL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM FOLINATE , OXALIPLATIN , -, CALCIUM LEVOFOLINATE , PARACETAMOL , -, -, -, -, Ifinatamab Deruxtecan

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  21. FLUOROURACIL , OXALIPLATIN , ABTL0812 Placebo, ABTL0812, IRINOTECAN , CALCIUM FOLINATE

    Lacuna Pharma Pty Ltd

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. FMX-103 1.5%

    VYNE Therapeutics

    Rosacea

    phase 2 small molecule completed

    1 trial

  23. FWD1802

    Forward Pharmaceuticals Co.,

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  24. FWY003, FWY003, Placebo to FWY003, FWY003

    Novartis Pharmaceuticals

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources